Colowick Alan 4
4 · Principia Biopharma Inc. · Filed Sep 28, 2020
Insider Transaction Report
Form 4
Colowick Alan
Director
Transactions
- Disposition to Issuer
Director Stock Option (right to buy)
2020-09-28−20,475→ 0 totalExercise: $17.00Exp: 2028-09-12→ Common Stock (20,475 underlying) - Disposition to Issuer
Director Stock Option (right to buy)
2020-09-28−47,724→ 0 totalExercise: $4.54Exp: 2027-06-26→ Common Stock (47,724 underlying) - Disposition to Issuer
Director Stock Option (right to buy)
2020-09-28−10,240→ 0 totalExercise: $31.77Exp: 2029-06-10→ Common Stock (10,240 underlying) - Disposition to Issuer
Director Stock Option (right to buy)
2020-09-28−10,240→ 0 totalExercise: $62.66Exp: 2030-06-03→ Common Stock (10,240 underlying)
Footnotes (1)
- [F1]Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options.